Eli Lilly and Co
LLY
NYSE
Pharmaceuticals
$1244.40
USD
-35.94 (-2.81%)
At close: Aug 20, 2026, 4:00 PM EDT
Market Cap $1.15T
Volume 2.4M
Revenue
$72.25B
TTM
+47.4%
YoY
Gross Margin
83%
TTM
+1.4%
YoY
Net Income
$25.28B
TTM
+127.6%
YoY
Operating Cash Flow
$20.48B
TTM
+119.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 12,729.0 | 15,557.7 | 17,600.8 | 19,292.0 | 19,799.0 |
YoY Growth | +45.2% | +37.6% | +53.9% | +42.6% | +55.5% |
Cost of Revenue | 2,225.0 | 2,447.8 | 3,008.3 | 3,371.7 | 3,577.0 |
Gross Profit | 10,504.0 | 13,109.9 | 14,592.5 | 15,920.3 | 16,222.0 |
Selling, General & Administrative | 2,468.0 | 2,753.0 | 2,740.7 | 3,131.4 | 2,934.0 |
Other Operating Expenses | 1,607.0 | 153.8 | 1,020.6 | 612.9 | 863.0 |
Total Operating Expenses | 6,809.0 | 6,242.9 | 7,227.0 | 7,545.8 | 7,307.0 |
Operating Income | 3,695.0 | 6,867.0 | 7,365.5 | 8,374.5 | 8,915.0 |
EBITDA | 5,765.0 | 7,499.3 | 8,856.1 | 9,573.1 | 10,287.0 |
Other Income / Expense | -239.0 | -90.6 | -133.1 | -108.3 | -65.0 |
Total Other Income / Expense | -239.0 | -90.6 | -133.1 | -108.3 | -65.0 |
Income Before Income Taxes | 3,456.0 | 6,776.4 | 7,232.4 | 8,266.2 | 8,850.0 |
Income Taxes | 697.0 | 1,115.9 | 1,649.9 | 1,628.5 | 1,454.0 |
Net Income | 2,759.0 | 5,660.5 | 5,582.5 | 6,637.7 | 7,396.0 |
Consolidated Net Income / Loss | 2,759.0 | 5,660.5 | 5,582.5 | 6,637.7 | 7,396.0 |
Net Income Attributable to Common Shareholders | 2,759.0 | 5,660.5 | 5,582.5 | 6,637.7 | 7,396.0 |
Basic EPS | $3.07 | $6.30 | $6.22 | $7.41 | $8.27 |
Diluted EPS | $3.06 | $6.29 | $6.21 | $7.39 | $8.26 |
Basic Shares Outstanding | 898.7M | 897.9M | 896.9M | 895.7M | 894.5M |
Diluted Shares Outstanding | 900.6M | 899.8M | 898.8M | 898.0M | 895.9M |